Relativity between the gene polymorphisms of LXR and metabolic syndrome

Abstract

Abstract:

Liver X receptor(LXR) is an important nuclear receptor in the body, which is a ligand-dependent protein. LXR is an integrator of hormonal and nutritional signal mediating changes to metabolic pathways of lipid and glucose within the body. It's involved in various common metabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, hyperlipidaemia, and so on. Some studies proved that a number of gene polymorphism sites in LXR were linked with metabolic diseases. Studying the pathological mechanism of LXR in metabolic diseases and researching the correlation between gene polymorphism of LXR and metabolic diseases are beneficial to detecting and assessing the risks of metabolic diseases genetically, which can discover and prevent the diseases early so as to improve the quality of life of patients and prolong living time. This review focuses on the metabolism of LXR and the correlation between the gene polymorphism and metabolic diseases of LXR.

Key words: liver X receptor, metabolic diseases, gene polymorphism

CLC Number:

R968

ZHAO Huijia, LI Ling, WEI Wanhui, XU Qian, SHI Yuying, YUE Jiang, WANG yanfeng, Ye Qifa. Relativity between the gene polymorphisms of LXR and metabolic syndrome[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 713-720.

References

［1］RankinenT , Sarzynski MA , Ghosh S, et al. Are There genetic paths common to obesity, cardiovascular disease outcomes, and cardiov- ascular risk factors［J］?Circ Res, 2015, 116(5): 909-922.
［2］Bi XK,Song JL,Gao J, et al. Activation of liver X receptor attenuates lysophosphatidylcholine-induced IL-8 expression in endothelial cells via the NF-κB pathway and SUMOylation［J］. J Cell Mol Med, 2016, 20(10): 1-10.
［3］Zhang L, Chen YL, Yang XX, et al. MEK1/2 inhibitors activate macrophage ABCG1 expression and reverse cholesterol transport-An anti-atherogenic function of ERK1/2 inhibition［J］. Biochimica et Biophysica Acta, 2016, (1861): 1180-1191.
［4］Kiss M, Czimmerer Z, Nagy L,et al. The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: From physiology to pathology［J］. J Allergy Clin Immunol， 2013, 132(2): 264-286.
［5］Huwait EA, Singh NN, Michael DR. Protein kinase C is involved in the induction of ATP-binding cassette transporter A1 expression by liver X receptor /retinoid X receptor agonist in human macrophages［J］.J Cell Biochem， 2015, 116(9): 2032-2038.
［6］Nagy L, Szanto A, Szatmari I, et al. Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response［J］. Physiol Rev, 2012, 92(2): 739-789.
［7］Venkateswaran A, Laffitte BA, Joseph SB,et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα［J］. Proc Natl Acad Sci USA,2000,97(22)：12097-12102.
［8］Hong YF, Kim H, Kim HS. Lactobacillus acidophilus K301 Inhibits Atherogenesis via Induction of 24 (S), 25- Epoxycholesterol-Mediated ABCA1 and ABCG1 Production and Cholesterol Efflux in Macrophages［J］. PLoS One, 2016, 11(4): 1-18.
［9］Fang L, Choi SH, Baek JS, Liu C. Control of Angiogenesis by AIBP-mediated Cholesterol Efflux［J］. Nature, 2013, 498(7452): 118-122.
［10］Hong C, Walczak R, Dhamko H, et al. Constitutive activation of LXR in macrophages regulates metabolic and inflammatory gene expression: identification of ARL7 as a direct target［J］. J Lipid Res，2011，52(3):531-539.
［11］Kirchgessner TG,Sleph P, Ostrowski J,et al. Beneficial and adverse effects of an lxr agonist on human lipid and lipoprotein metabolism and circulating neutrophils［J］.Cell Metabolism, 2016,24(2):223-233.
［12］Peet DJ, Turley SD, Ma W, et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα［J］. Cell，1998，93(5):693-704.
［13］Hsieh J, Koseki M, Molusky MM, et al. TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis［J］.Nature, 2016, 535(7611): 303-307.
［14］Hgmoen strand OA,Gikling I, Sylte I,et al. Development of new LXR modulators that regulate LXR target genes and reduce lipogenesis in human cell models［J］. Eur J Med Chem, 2014, 74: 258-263.
［15］Kawase A, Hata S, Takagi M, et al. Pravastatin modulate niemann-pick c1-like 1 and atp-binding cassette g5 and g8 to influence intestinal cholesterol absorption［J］. J Pharm Pharm Sci, 2015, 18(5): 765-772.
［16］van der Veen JN, van Dijk TH, Vrins CL，et al. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol［J］.J Biol Chem，2009，284(29):19211-19219.
［17］Kartawijaya M, Han HW, Kim Y，et al. Genistein upregulates LDLR levels via JNK-mediated activation of SREBP-2［J］. Food Nutr Res, 2016, 60(31120): 302-309.
［18］Guo D, Reinitz F, Youssef F, et al. An LXR agonist promotes GBM cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR -dependent pathway［J］. Cancer Discov, 2011, 1(5): 442-456.
［19］Shavva VS, Bogomolova AM, Nikitin AA,et al. Insulin-Mediated Downregulation of Apolipoprotein A-I Gene in Human Hepatoma Cell Line HepG2: The Role of Interaction between FOXO1 and LXRβ Transcription Factors［J］. J Cell Biochem, 2016,doi: 10.1002/jcb.25651.
［20］Mitro N, Mak PA, Vargas L，et al.The nuclear receptor LXR is a glucose sensor［J］. Nature，2007, 445(7124):219-223.
［21］Pettersson AM, Stenson BM, Lorente-Cebrián S，et al.LXR is a negative regulator of glucose uptake in human adipocytes［J］. Diabetologia, 2013, 56(9): 2044-2054.
［22］Korach-André M, Archer A, Barros RP, et al. Both liver-X receptor (LXR) isoforms control energy expenditure by regulating brown adipose tissue activity［J］. Proc Natl Acad Sci USA, 2011, 108(1): 403-408.
［23］Stenson BM, Rydén M, Steffensen KR, et al. Activation of liver X receptor regulates substrate oxidation in white adipocytes［J］. Endocrinology，2009，150(9):4104-4113.
［24］Ketterer C, Müssig K,Machicao F,et al. Genetic variation within the NR1H2 gene encoding liver X receptor β associates with insulin secretion in subjects at increased risk for type 2 diabetes［J］. J Mol Med, 2011, (89): 75-81.
［25］Solaas K, Legry V, Retterstol K, et al. Suggestive evidence of associations between liver X receptor b polymorphisms with type 2 diabetes mellitus and obesity in three cohort studies: HUNT2 (Norway), MONICA (France) and HELENA (Europe)［J］. BMC Medical Genetics, 2010, 11(144): 234-244.
［26］Sharma KL, Misra S, Kumar A,et al. Association of liver X receptors (LXRs) genetic variants to gallbladder cancer susceptibility［J］. Tumour Biol, 2013, 34(6): 3959-3966.
［27］Stender S, Frikke-Schmidt R, Anestis A,et al. Genetic Variation in Liver X Receptor Alpha and Risk of Ischemic Vascular Disease in the General Population［J］. Arterioscler Thromb Vasc Biol, 2011, (31): 2990-2996.
［28］Yang JS, Hao JJ, Wang SS,et al. Association between the LXRα polymorphism and stroke in a Chinese population［J］. Genet Mol Res, 2015, 14(1): 1757-1762.
［29］Han M, Liang L, Liu LR, et al. Liver X Receptor Gene Polymorphisms in Tuberculosis: Effect on Susceptibility［J］. PLoS ONE,2014,9(5):e95954. doi:10.1371/journal.pone.0095954.
［30］Legry V, Bokor S, Beghin L,et al. Associations between common genetic polymorphisms in the liver X receptor alpha and its target genes with the serum HDL-cholesterol concentration in adolescents of the HELENA Study［J］. Atherosclerosis, 2011, (216): 166-169.
［31］Price ET, Pacanowski MA, Martin MA,et al. Liver X receptorα gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy results from the INVEST-GENES study［J］. Pharmacogenet Genomics, 2011, 21(6): 333-340.
［32］Zhou YF, Zhang J, Li ZX, et al. Association of liver X receptor α (LXRα) gene polymorphism and coronary heart disease, serum lipids and glucose levels［J］. Lipids Health Dis, 2014, 13(34): 25-29.
［33］Adighibe O, Arepalli S, Duckworth J,et al. Genetic variability at the LXR gene (NR1H2) may contribute to the risk of Alzheimer's disease［J］. Neurobiol Aging，2006, 27(10): 1431-1434.
［34］Infante J, Rodríguez-Rodríguez E, Mateo I,et al. Gene-gene interaction between heme oxygenase-1 and liver X receptor- and Alzheimer's disease risk［J］.Neurobiol Aging，2010, 31(4)：710-714.
［35］Natunen T, Martiskainen H, Sarajrvi T,et al.Effects of NR1H3 genetic variation on the expression of liver x receptor a and the progression of Alzheimer's disease［J］.PLoS One, 2013, 8(11): e80700.
［36］汪江林，左笑丛，杨梦等. 钙调神经磷酸酶/NFATc信号通路介导他克莫司诱导移植后糖尿病的研究进展［J］. 中国临床药理学与治疗学，2014,19（1）：74-80.
［37］Sabine G , Maximilian J, Maciej M,et al. Risk factors of metabolic disorders after liver transplantation: an analysis of data from fasted patient.［J］. Transplantation, 2015, 99(6): 1243-1249.
［38］Chang AL, Cortez AR，Bondoc A,et al. Metabolic syndrome in liver transplantation: A preoperative and postoperative concern［J］. Surgery, 2016,160(4):1111-1117.
［39］Kiss E, Popovic Z, Bedke J,et al.Suppression of chronic damage in renal allografts byLiver X receptor (LXR) activation relevant contributionof macrophage LXRα［J］. Am J Pathol , 2011, 179(1): 92-103.
［40］Wang Y, Li C, Cheng K,et al. Activation of Liver X Receptor Improves Viability of Adipose-Derived Mesenchymal Stem Cells to Attenuate Myocardial Ischemia Injury Through TLR4/NF-jB and Keap-1/Nrf-2 Signaling Pathways［J］. Antioxid Redox Signal，2014, 21(18): 2543-2557.
［41］Bhargava M, Viken KJ, Dey S,et al. Proteome profiling in lung injury after hematopoietic stem cell transplantation［J］.Biol Blood Marrow Transplant，2016，22(8): 1383-1390.
［42］Ergen HA, Zeybek U, Gok O,et al. Investigation of ABCA1 C69T polymorphism in patients with type 2 diabetes mellitus［J］. Biochem Med (Zagreb) , 2012, 22(1): 114-120.
［43］Kalantarian S, Rimm EB, Herrington DM,et al. Dietary macronutrients, genetic variation, and progression of coronary atherosclerosis among women［J］. Am Heart J, 2014, 167(4): 627-635.

[1]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[2]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[3]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[4]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[5]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[6]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[7]	WANG Chunling, ZHOU Renjing, FENG Rui, WU Yanneng. Effect of adiponectin 45 T/G gene polymorphism on type 2 diabetes treated with liraglutide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 312-317.
[8]	LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun. Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258.
[9]	YANG Chunyan, ZHANG Wen, WANG Peipei, PENG Jing, JIANG Jia, SONG Jing, LIU Jun, LI Yueran, YANG Kui, WANG Sheng, XU Zhenyu, LUAN Jiajie. Distribution of gene polymorphism in folate metabolism pathway and its effect on serumhomocysteine concentration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1259-1264.
[10]	. Research Progress of Pharmacogenomics of Dabigatran Etexilate and Rivaroxaban [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1200-1207.
[11]	WANG Fengling, MENG Xiangyun, CHEN Zhengxu, CAO Rongjuan, HE Zhengmin, YE Xi, WANG Cong, LI Qi. Analysis on genetic polymorphism of SLCO1B1 and ApoE in patients with cardiovascular diseases of Han nationality in Anhui area and its clinical significance for individualized use of statins [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 40-48.
[12]	XU Honglei, XU Bingxin, ZU Qing, ZHAO Yan, GAO Pengfei, YU Yang. Effects of CYP2C19 gene polymorphism on the clinical prognosis of clopidogrel in elderly patients with acute cerebral infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1014-1020.
[13]	PENG Jing, LIU Jun, XU Huifang, LI Yueran, JIANG Jia, WANG Sheng, ZHOU Dexi, ZHU Yanhong, YANG Kui, LUAN Jiajie. Correlation study between cytochrome P4502C19 gene polymorphism or metabolic type and ADP induced-platelet aggregation inhibition and clopidogrel resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 746-751.
[14]	TANG Mufei, SHEN Yunzhu, ZHANG Baoguo. Influence of CYP2D6 gene polymorphism on the effect of tropisetron in preventing chemotherapy induced nausea and vomiting [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 817-822.
[15]	ZHAO Hailing, ZHANG Haojun, ZHAO Tingting, YAN Meihua, DONG Xi, MA Liang, LI Ping. Association between the polymorphism of PNPLA2 gene and the risk of ischemic stroke in type 2 diabetic patients in Chinese Han Population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 664-669.